Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children63510.24287/1726-1708-2022-21-4-124-133CLINICAL OBSERVATIONSКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯLong-term musculoskeletal side effects in patients with neuroblastoma who have completed specific therapy (case reports and literature review)Отдаленные побочные эффекты со стороны костно-мышечной системы у пациентов с нейробластомой, завершивших специфическую терапию (клинические примеры и обзор литературы)https://orcid.org/0000-0001-7479-0007UtalievaD. T.УталиеваД. Т.
Russian Federation

Dinara T. Utalieva, a pediatric oncologist of the Department of Clinical Oncology

117997, Moscow, Samory Mashela St., 1

Уталиева Динара Тиморкановна, врач-детский онколог отделения клинической онкологии

117997, Москва, ул. Саморы Машела, 1

 

dinara.utalieva@fccho-moscow.ruhttps://orcid.org/0000-0002-3704-8783KachanovD. Yu.КачановД. Ю.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0002-9177-5252IlyinaE. Yu.ИльинаЕ. Ю.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0001-5318-8033PopaA. V.ПопаА. В.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0002-2537-6157NechesnyukA. V.НечеснюкА. В.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0002-3767-4477ShamanskayaT. V.ШаманскаяТ. В.
Russian Federation

Moscow

Москва

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России261220222141241332007202207092022Copyright ©; 2022, «D. Rogachev NMRCPHOI»Copyright ©; 2022, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2022«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/635

Neuroblastoma (NB) is the most common extracranial solid tumor in children. The stratification of patients into risk groups has led to the development of therapeutic protocols with intensification of therapy in high-risk patients and minimal treatment, up to the complete abandonment of chemotherapy in patients with a potentially favorable long-term prognosis. The implementation of multimodal therapy in the intermediate/high-risk group patients significantly improved long-term survival rates. However, anticancer treatment inevitably leads to a wide range of undesirable effects and long-term consequences, including negative effects on the musculoskeletal tissue and teeth. The main factors leading to the pathology of the musculoskeletal system include chemotherapy, including high-dose chemotherapy with autologous hematopoietic stem cell transplantation, radiation therapy and other methods of treatment. In addition, the localization of a primary tumor and metastases creates a potential threat of the development of undesirable effects on the musculoskeletal system, including for patients from the observation group. The article presents a description of clinical cases of musculoskeletal toxicity in patients with NB who completed specific treatment with a literature review on this topic. The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.

Нейробластома (НБ) является одной из частых экстракраниальных солидных опухолей у детей. Стратификация пациентов на группы риска привела к разработке лечебных протоколов с интенсификацией терапии у детей с НБ группы высокого риска и минимализацией лечения вплоть до полного отказа от химиотерапии у больных с потенциально благоприятным отдаленным прогнозом. Проведение мультимодальной терапии в группе пациентов промежуточного/высокого риска значительно улучшило показатели долгосрочной выживаемости. Однако противоопухолевое лечение может провоцировать развитие нежелательных эффектов со стороны органов и систем, включая костно-мышечную ткань и зубы. К основным факторам, приводящим к развитию патологии костно-мышечной системы, относят полихимиотерапию, включая высокодозную химиотерапию с аутологичной трансплантацией гемопоэтических стволовых клеток, лучевую терапию и другие методы лечения. Кроме этого, анатомическая локализация первичной опухоли и метастазов создает потенциальную угрозу развития нежелательных эффектов со стороны костно-мышечной системы, в том числе и для пациентов группы наблюдения. В статье описаны клинические случаи костно-мышечной токсичности у пациентов с НБ, завершивших специфическое лечение, и представлен литературный обзор по данной тематике. Родители пациентов дали согласие на использование информации, в том числе фотографий детей, в научных исследованиях и публикациях.

neuroblastomachildrenmusculoskeletal systemlong-term side effectsнейробластомадетикостно-мышечная системаотдаленные побочные эффекты1. Berthold F., Hero B. Neuroblastoma: Current drug therapy recommendations as part of the total treatment approach. Drugs 2000; 59 (6): 1261–77. DOI:10.2165/00003495-200059060-00006Berthold F., Hero B. Neuroblastoma: Current drug therapy recommendations as part of the total treatment approach. Drugs 2000; 59 (6): 1261–77. DOI:10.2165/00003495-200059060-000062. Berthold F., Simon T. Clinical presentation. In: Book Neuroblastoma. Cheung N.-K., Cohn S. (eds.). Berlin, Heidelberg: Springer-Verlag; 2005. Рр. 63–86.Berthold F., Simon T. Clinical presentation. In: Book Neuroblastoma. Cheung N.-K., Cohn S. (eds.). Berlin, Heidelberg: Springer-Verlag; 2005. Рр. 63–86.3. Brodeur G.M. Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 2003; 3 (3): 203–16. DOI:10.1038/nrc1014Brodeur G.M. Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 2003; 3 (3): 203–16. DOI:10.1038/nrc10144. Hero B., Simon T., Spitz R., Ernestus K., Gnekow A.K., Scheel-Walter H.G., et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol 2008; 26 (9): 1504–10. DOI:10.1200/JCO.2007.12.3349Hero B., Simon T., Spitz R., Ernestus K., Gnekow A.K., Scheel-Walter H.G., et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol 2008; 26 (9): 1504–10. DOI:10.1200/JCO.2007.12.33495. Pinto N.R., Applebaum M.A., Volchenboum S.L., Matthay K.K., London W.B., Ambros P.F., et al. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol 2015; 33 (27): 3008–17. DOI:10.1200/JCO.2014.59.4648Pinto N.R., Applebaum M.A., Volchenboum S.L., Matthay K.K., London W.B., Ambros P.F., et al. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol 2015; 33 (27): 3008–17. DOI:10.1200/JCO.2014.59.46486. Hudson M.M., Ness K.K., Gurney J.G., Mulrooney D.A., Chemaitilly W., Krull K.R., et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 2013; 309 (22): 2371–81. DOI:10.1001/jama.2013.6296Hudson M.M., Ness K.K., Gurney J.G., Mulrooney D.A., Chemaitilly W., Krull K.R., et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 2013; 309 (22): 2371–81. DOI:10.1001/jama.2013.62967. Cohen L.E., Gordon J.H., Popovsky E.Y., Gunawardene S., DuffeyLind E., Lehmann L.E., et al. Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: High incidence of endocrine and growth problems. Bone Marrow Transplant 2014; 49: 502–8. DOI:10.1038/bmt.2013.218.Cohen L.E., Gordon J.H., Popovsky E.Y., Gunawardene S., DuffeyLind E., Lehmann L.E., et al. Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: High incidence of endocrine and growth problems. Bone Marrow Transplant 2014; 49: 502–8. DOI:10.1038/bmt.2013.218.8. Laverdie`re C., Cheung N.V., Kushner B.H., Kramer K., Modak S., LaQuaglia M.P., et al. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 2005; 45 (3): 324–32. DOI:10.1002/pbc.20331Laverdie`re C., Cheung N.V., Kushner B.H., Kramer K., Modak S., LaQuaglia M.P., et al. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 2005; 45 (3): 324–32. DOI:10.1002/pbc.203319. Laverdière C., Liu Q., Yasui Y., Nathan P.C., Gurney J., Stovall M., et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009; 101 (16): 1131–40. DOI:10.1093/jnci/djp230Laverdière C., Liu Q., Yasui Y., Nathan P.C., Gurney J., Stovall M., et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009; 101 (16): 1131–40. DOI:10.1093/jnci/djp23010. Van Santen Н.М., de Kraker J., Vulsma T. Endocrine late effects from multi-modality treatment of neuroblastoma. Eur J Cancer 2005; 41 (12): 1767–74. DOI:10.1016/j.ejca.2005.02.036Van Santen Н.М., de Kraker J., Vulsma T. Endocrine late effects from multi-modality treatment of neuroblastoma. Eur J Cancer 2005; 41 (12): 1767–74. DOI:10.1016/j.ejca.2005.02.03611. Kushner B.H., Budnick A., Kramer K., Modak S., Cheung N.K. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 2006; 107 (2): 417–22. DOI:10.1002/cncr.22004Kushner B.H., Budnick A., Kramer K., Modak S., Cheung N.K. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 2006; 107 (2): 417–22. DOI:10.1002/cncr.2200412. Bertolini P., Lassalle M., Mercier G., Raquin M.A., Izzi G., Corradini N., et al. Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004; 26: 649–55. DOI:10.1097/01.mph.0000141348.62532.73Bertolini P., Lassalle M., Mercier G., Raquin M.A., Izzi G., Corradini N., et al. Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004; 26: 649–55. DOI:10.1097/01.mph.0000141348.62532.7313. Grewal S., Merchant T., Reymond R., McInerney M., Hodge C., Shearer P. Auditory late effects of childhood cancer therapy: A report from the children’s oncology group. Pediatrics 2010; 125: 938–50. DOI:10.1542/peds.2009-1597Grewal S., Merchant T., Reymond R., McInerney M., Hodge C., Shearer P. Auditory late effects of childhood cancer therapy: A report from the children’s oncology group. Pediatrics 2010; 125: 938–50. DOI:10.1542/peds.2009-159714. Gurney J.G., Tersak J.M., Ness K.K., Landier W., Matthay K.K., Schmidt M.L. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: A report from the children’s oncology group. Pediatrics 2007; 120: e1229–36. DOI:10.1542/peds.2007-0178Gurney J.G., Tersak J.M., Ness K.K., Landier W., Matthay K.K., Schmidt M.L. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: A report from the children’s oncology group. Pediatrics 2007; 120: e1229–36. DOI:10.1542/peds.2007-017815. Haghiri S., Fayech C., Mansouri I., Dufour C., Pasqualini C., Bolle S., et al. Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue. Bone Marrow Transplant 2021; 56 (8): 1984–97. DOI:10.1038/s41409-021-01258-1Haghiri S., Fayech C., Mansouri I., Dufour C., Pasqualini C., Bolle S., et al. Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue. Bone Marrow Transplant 2021; 56 (8): 1984–97. DOI:10.1038/s41409-021-01258-116. Mostoufi-Moab S., Ward L.M. Skeletal Morbidity in Children and Adolescents during and following Cancer Therapy. Horm Res Paediatr 2019; 91: 137–51. DOI:10.1159/000494809Mostoufi-Moab S., Ward L.M. Skeletal Morbidity in Children and Adolescents during and following Cancer Therapy. Horm Res Paediatr 2019; 91: 137–51. DOI:10.1159/00049480917. Oskarsson T., Duun-Henriksen A.K., Bautz A., Montgomery S., HarilaSaari A., Petersen C., et al. Skeletal adverse events in childhood cancer survivors: An Adult Life after Childhood Cancer in Scandinavia cohort study. Int J Cancer 2021; 149 (11): 1863–76. DOI:10.1002/ijc.33741Oskarsson T., Duun-Henriksen A.K., Bautz A., Montgomery S., HarilaSaari A., Petersen C., et al. Skeletal adverse events in childhood cancer survivors: An Adult Life after Childhood Cancer in Scandinavia cohort study. Int J Cancer 2021; 149 (11): 1863–76. DOI:10.1002/ijc.3374118. Hovi L., Era P., Rautonen J., Siimes M.A. Impaired muscle strength in female adolescents and young adults surviving leukemia in childhood. Cancer 1993; 72 (1): 276–81. DOI:10.1002/1097-0142(19930701)72:1<276:aid-cncr2820720148>3.0.co;2-2Hovi L., Era P., Rautonen J., Siimes M.A. Impaired muscle strength in female adolescents and young adults surviving leukemia in childhood. Cancer 1993; 72 (1): 276–81. DOI:10.1002/1097-0142(19930701)72:1<276:aid-cncr2820720148>3.0.co;2-219. Willman K.Y., Cox R.S., Donaldson S.S. Radiation induced height impairment in pediatric Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1994; 28 (1): 85–92. DOI:10.1016/0360-3016(94)90144-9Willman K.Y., Cox R.S., Donaldson S.S. Radiation induced height impairment in pediatric Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1994; 28 (1): 85–92. DOI:10.1016/0360-3016(94)90144-920. Заева Г.Е., Валиев Т.Т., Гавриленко Т.Ф. Моисеенко Е.И., Медведовская Е.Г., Михайлова С.Н, и др. Отдаленные последствия терапии злокачественных опухолей у детей: 35-летний опыт клинических наблюдений. Современная онкология 2015; 18 (1): 55–60.Заева Г.Е., Валиев Т.Т., Гавриленко Т.Ф. Моисеенко Е.И., Медведовская Е.Г., Михайлова С.Н, и др. Отдаленные последствия терапии злокачественных опухолей у детей: 35-летний опыт клинических наблюдений. Современная онкология 2015; 18 (1): 55–60.21. Голоунина О.О., Павлова М.Г., Белая Ж.Е., Ким Е.И., Глинкина И.В., Моргунова Т.Б. и др. Функциональное состояние эндокринной системы и минеральная плотность костной ткани в отдаленном периоде после комбинированного лечения злокачественных опухолей головного мозга в детском и молодом возрасте. Проблемы эндокринологии 2021; 67 (1): 31–40. DOI:10.14341/probl12680Голоунина О.О., Павлова М.Г., Белая Ж.Е., Ким Е.И., Глинкина И.В., Моргунова Т.Б. и др. Функциональное состояние эндокринной системы и минеральная плотность костной ткани в отдаленном периоде после комбинированного лечения злокачественных опухолей головного мозга в детском и молодом возрасте. Проблемы эндокринологии 2021; 67 (1): 31–40. DOI:10.14341/probl1268022. Hobbie W.L., Li Y., Carlson C., Goldfarb S., Laskin B., Denburg M., et al. Late effects in survivors of highrisk neuroblastoma following stem cell transplant with and without total body irradiation. Pediatr Blood Cancer 2022; 69 (3): e29537. DOI:10.1002/pbc.29537Hobbie W.L., Li Y., Carlson C., Goldfarb S., Laskin B., Denburg M., et al. Late effects in survivors of highrisk neuroblastoma following stem cell transplant with and without total body irradiation. Pediatr Blood Cancer 2022; 69 (3): e29537. DOI:10.1002/pbc.2953723. Baek K.H., Lee W.Y., Oh K.W. Kim H.S., Han J.H., Kang M.I., et al. Changes in the serum growth factors and osteoprotegerin after bone marrow transplantation: impact on bone and mineral metabolism. J Clin Endocrinol Metab 2004; 89 (3): 1246–54. DOI:10.1210/jc.2003-031206Baek K.H., Lee W.Y., Oh K.W. Kim H.S., Han J.H., Kang M.I., et al. Changes in the serum growth factors and osteoprotegerin after bone marrow transplantation: impact on bone and mineral metabolism. J Clin Endocrinol Metab 2004; 89 (3): 1246–54. DOI:10.1210/jc.2003-03120624. Davies J.H., Evans B.A., Jenney M.E., Gregory J.W. Effects of chemotherapeutic agents on the function of primary human osteoblast-like cells derived from children. J Clin Endocrinol Metab 2003; 88 (12): 6088–97. DOI:10.1210/jc.2003-030712Davies J.H., Evans B.A., Jenney M.E., Gregory J.W. Effects of chemotherapeutic agents on the function of primary human osteoblast-like cells derived from children. J Clin Endocrinol Metab 2003; 88 (12): 6088–97. DOI:10.1210/jc.2003-03071225. Amrein K., Scherkl M., Hoffmann M., Neuwersch-Sommeregger S., Köstenberger M., Tmava Berisha A., et al. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr 2020; 74 (11): 1498–513. DOI:10.1038/s41430-020-0558-yAmrein K., Scherkl M., Hoffmann M., Neuwersch-Sommeregger S., Köstenberger M., Tmava Berisha A., et al. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr 2020; 74 (11): 1498–513. DOI:10.1038/s41430-020-0558-y26. Chow E.J., Anderson L., Baker K.S., Bhatia S., Guilcher G.M., Huang J.T., et al. Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report. Biol Blood Marrow Transplant 2016; 22 (5): 782–95. DOI:10.1016/j.bbmt.2016.01.023Chow E.J., Anderson L., Baker K.S., Bhatia S., Guilcher G.M., Huang J.T., et al. Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report. Biol Blood Marrow Transplant 2016; 22 (5): 782–95. DOI:10.1016/j.bbmt.2016.01.02327. Utriainen P., Vatanen A., Toiviainen-Salo S., Saarinen-Pihkala U., Mäkitie O., Jahnukainen K., et al. Skeletal outcome in long-term survivors of childhood high-risk neuroblastoma treated with high-dose therapy and autologous stem cell rescue. Bone Marrow Transplant 2017; 52: 711–6. DOI:10.1038/bmt.2016.345Utriainen P., Vatanen A., Toiviainen-Salo S., Saarinen-Pihkala U., Mäkitie O., Jahnukainen K., et al. Skeletal outcome in long-term survivors of childhood high-risk neuroblastoma treated with high-dose therapy and autologous stem cell rescue. Bone Marrow Transplant 2017; 52: 711–6. DOI:10.1038/bmt.2016.34528. Goren M.P., Wright R.K., Horowitz M.E., Pratt C.B. Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna. Cancer Treat Rep 1987; 71 (2): 127–30.Goren M.P., Wright R.K., Horowitz M.E., Pratt C.B. Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna. Cancer Treat Rep 1987; 71 (2): 127–30.29. Tillman V., Darlington A.S., Eiser C., Bishop N.J., Davies H.A. Male sex and low physical activity are associated with reduced spine bone mineral density in survivors of childhood acute lymphoblastic leukemia. J Bone Miner Res 2002; 17 (6): 1073–80. DOI:10.1359/jbmr.2002.17.6.1073Tillman V., Darlington A.S., Eiser C., Bishop N.J., Davies H.A. Male sex and low physical activity are associated with reduced spine bone mineral density in survivors of childhood acute lymphoblastic leukemia. J Bone Miner Res 2002; 17 (6): 1073–80. DOI:10.1359/jbmr.2002.17.6.107330. Achermann J.C., Hindmarsh P.C., Brook C.G. The relationship between the growth hormone and insulin-like growth factor axis in long-term survivors of childhood brain tumours. Clin Endocrinol (Oxf) 1998; 49 (5): 639–45. DOI:10.1046/j.1365-2265.1998.00585Achermann J.C., Hindmarsh P.C., Brook C.G. The relationship between the growth hormone and insulin-like growth factor axis in long-term survivors of childhood brain tumours. Clin Endocrinol (Oxf) 1998; 49 (5): 639–45. DOI:10.1046/j.1365-2265.1998.0058531. Shalet S.M., Gibson B., Swindell R., Pearson D. Eff ects of spinal irradiation on growth. Arch Dis Child 1987; 62 (5): 461–4. DOI:10.1136/adc.62.5.461Shalet S.M., Gibson B., Swindell R., Pearson D. Eff ects of spinal irradiation on growth. Arch Dis Child 1987; 62 (5): 461–4. DOI:10.1136/adc.62.5.46132. Donaubauer A.J., Deloch L., Becker I., Fietkau R., Frey B., Gaipl U.S. The Influence of Radiation on Bone and Bone Cells-Differential Effects on Osteoclasts and Osteoblasts. Int J Mol Sci 2020; 21 (17): 6377. DOI:10.3390/ijms21176377Donaubauer A.J., Deloch L., Becker I., Fietkau R., Frey B., Gaipl U.S. The Influence of Radiation on Bone and Bone Cells-Differential Effects on Osteoclasts and Osteoblasts. Int J Mol Sci 2020; 21 (17): 6377. DOI:10.3390/ijms2117637733. Al-Tonbary Y.A., El-Ziny M.A., Elsharkawy A.A., El-Hawary AK, El-Ashry R, Fouda AE. Bone mineral density in newly diagnosed children with neuroblastoma. Pediatr Blood Cancer 2011; 56 (2): 202–5. DOI:10.1002/pbc.22880Al-Tonbary Y.A., El-Ziny M.A., Elsharkawy A.A., El-Hawary AK, El-Ashry R, Fouda AE. Bone mineral density in newly diagnosed children with neuroblastoma. Pediatr Blood Cancer 2011; 56 (2): 202–5. DOI:10.1002/pbc.2288034. Уталиева Д.Т., Бабаханова С.Б., Ильина Е.Ю., Андреева Н.А., Ликарь Ю.Н., Щербаков А.П., и др. Развитие первичного гипотиреоза у пациента с нейробластомой группы высокого риска после проведения 131I-МЙБГ-терапии: описание клинического наблюдения и обзор литературы. Педиатрия. Журнал им. Г.Н. Сперанского 2021; 100 (3): 258–66. DOI:10.24110/0031-403X-2021-100-3-258-266Уталиева Д.Т., Бабаханова С.Б., Ильина Е.Ю., Андреева Н.А., Ликарь Ю.Н., Щербаков А.П., и др. Развитие первичного гипотиреоза у пациента с нейробластомой группы высокого риска после проведения 131I-МЙБГ-терапии: описание клинического наблюдения и обзор литературы. Педиатрия. Журнал им. Г.Н. Сперанского 2021; 100 (3): 258–66. DOI:10.24110/0031-403X-2021-100-3-258-26635. Lenchik L., Rogers L.F., Delmas P.D., Genant H.K. Diagnosis of osteoporotic vertebral fractures: importance of recognition and description by radiologists. AJR Am J Roentgenol 2004; 183 (4): 949–58. DOI:10.2214/ajr.183.4.1830949Lenchik L., Rogers L.F., Delmas P.D., Genant H.K. Diagnosis of osteoporotic vertebral fractures: importance of recognition and description by radiologists. AJR Am J Roentgenol 2004; 183 (4): 949–58. DOI:10.2214/ajr.183.4.183094936. Vasikaran S., Eastell R., Bruyère O., Foldes A.J., Garnero P., Griesmacher A., et al. Bone Marker Standards Working Group. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011; 22 (2): 391–420. DOI:10.1007/s00198-010-1501-1Vasikaran S., Eastell R., Bruyère O., Foldes A.J., Garnero P., Griesmacher A., et al. Bone Marker Standards Working Group. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011; 22 (2): 391–420. DOI:10.1007/s00198-010-1501-137. Dupont C., Chouraqui J.P., Linglart A., Bocquet A., Darmaun D., Feillet F., et al. Committee on Nutrition of the French Society of Pediatrics. Nutritional management of cow's milk allergy in children: An update. Arch Pediatr 2018; 25 (3): 236–43. DOI:10.1016/j.arcped.2018.01.007Dupont C., Chouraqui J.P., Linglart A., Bocquet A., Darmaun D., Feillet F., et al. Committee on Nutrition of the French Society of Pediatrics. Nutritional management of cow's milk allergy in children: An update. Arch Pediatr 2018; 25 (3): 236–43. DOI:10.1016/j.arcped.2018.01.00738. Calcium calculator. [Электронный ресурс] URL: https://www.osteoporosis.foundation/educational-hub/topic/calcium/list-of-calcium-contentof-common-foods (дата обращения 28.07.2021).Calcium calculator. [Электронный ресурс] URL: https://www.osteoporosis.foundation/educational-hub/topic/calcium/list-of-calcium-contentof-common-foods (дата обращения 28.07.2021).39. Naghshi S., Naemi M., Sadeghi O., Darooghegi Mofrad M., Moezrad M., Azadbakht L. Total, dietary, and supplemental calcium intake and risk of all-cause cardiovascular, and cancer mortality: a systematic review and dose-response meta-analysis of prospective cohort studies. Crit Rev Food Sci Nutr 2022; 62 (21): 5733–43. DOI:10.1080/10408398.2021.1890690Naghshi S., Naemi M., Sadeghi O., Darooghegi Mofrad M., Moezrad M., Azadbakht L. Total, dietary, and supplemental calcium intake and risk of all-cause cardiovascular, and cancer mortality: a systematic review and dose-response meta-analysis of prospective cohort studies. Crit Rev Food Sci Nutr 2022; 62 (21): 5733–43. DOI:10.1080/10408398.2021.189069040. Cross S.F., Pozza L.D., Munns C.F. Hypercalcemia and osteoblastic lesions induced by 13-cis-retinoic acid mimicking relapsed neuroblastoma. Pediatr Blood Cancer 2009; 53 (4): 666–8. DOI:10.1002/pbc.22052Cross S.F., Pozza L.D., Munns C.F. Hypercalcemia and osteoblastic lesions induced by 13-cis-retinoic acid mimicking relapsed neuroblastoma. Pediatr Blood Cancer 2009; 53 (4): 666–8. DOI:10.1002/pbc.2205241. Hobbie W.L., Mostoufi S.M., Carlson C.A., Gruccio D., Ginsberg J.P. Prevalence of advanced bone age in a cohort of patients who received cis-retinoic acid for high-risk neuroblastoma. Pediatr Blood Cancer 2011; 56: 474–6. DOI:10.1002/pbc.22839Hobbie W.L., Mostoufi S.M., Carlson C.A., Gruccio D., Ginsberg J.P. Prevalence of advanced bone age in a cohort of patients who received cis-retinoic acid for high-risk neuroblastoma. Pediatr Blood Cancer 2011; 56: 474–6. DOI:10.1002/pbc.2283942. Сагоян Г.Б., Шаманская Т.В., Качанов Д.Ю., Большаков Н.А., Терещенко Г.В., Ликарь Ю.Н. и др. Случай развития костной токсичности, имитирующей рецидив основного заболевания, у ребенка с нейробластомой на фоне терапии 13-цис-Ретиноевой кислотой. Российский журнал детской гематологии и онкологии 2018; 5 (2): 60–5.Сагоян Г.Б., Шаманская Т.В., Качанов Д.Ю., Большаков Н.А., Терещенко Г.В., Ликарь Ю.Н. и др. Случай развития костной токсичности, имитирующей рецидив основного заболевания, у ребенка с нейробластомой на фоне терапии 13-цис-Ретиноевой кислотой. Российский журнал детской гематологии и онкологии 2018; 5 (2): 60–5.43. Standeven A.M., Davies P.J., Chandraratna R.A., Mader D.R., Johnson A.T., Thomazy V.A. Retinoid-induced epiphyseal plate closure in guinea pigs. Fund Appl Toxicol 1996; 34 (1): 91–8.Standeven A.M., Davies P.J., Chandraratna R.A., Mader D.R., Johnson A.T., Thomazy V.A. Retinoid-induced epiphyseal plate closure in guinea pigs. Fund Appl Toxicol 1996; 34 (1): 91–8.44. Ремизов А.Н., Горохова Е.В., Качанов Д.Ю., Меришавян О.Б., Хомякова С.П., Озеров С.С. и др. Ортопедические нарушения у детей с нейробластомой при интраканальном распространении: опыт НМИЦ ДГОИ им. Дмитрия Рогачева. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2021; 20 (4): 56–68. DOI:10.24287/1726-1708-2021-20-4-56-68Ремизов А.Н., Горохова Е.В., Качанов Д.Ю., Меришавян О.Б., Хомякова С.П., Озеров С.С. и др. Ортопедические нарушения у детей с нейробластомой при интраканальном распространении: опыт НМИЦ ДГОИ им. Дмитрия Рогачева. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2021; 20 (4): 56–68. DOI:10.24287/1726-1708-2021-20-4-56-6845.Mayfield J.K., Riseborough E.J., Jaffe N., Nehme M.E. Spinal deformity in children treated for neuroblastoma. J Bone Joint Surg Am 1981; 63 (2): 183–93.Mayfield J.K., Riseborough E.J., Jaffe N., Nehme M.E. Spinal deformity in children treated for neuroblastoma. J Bone Joint Surg Am 1981; 63 (2): 183–93.46. De Jonge T., Slullitel H., Dubousset J., Miladi L., Wicart P., Illés T. Late-onset spinal deformities in children treated by laminectomy and radiation therapy for malignant tumours. Eur Spine J 2005; 14 (8): 765–71. DOI:10.1007/s00586-004-0778-1De Jonge T., Slullitel H., Dubousset J., Miladi L., Wicart P., Illés T. Late-onset spinal deformities in children treated by laminectomy and radiation therapy for malignant tumours. Eur Spine J 2005; 14 (8): 765–71. DOI:10.1007/s00586-004-0778-147. Halperson E., Matalon V., Goldstein G., Spilberg S.S., Herzog K., Fux-Noy A., et al. The prevalence of dental developmental anomalies among childhood cancer survivors according to types of anticancer treatment. Sci Rep 2022; 12 (1): 4485. DOI:10.1038/s41598-022-08266-1Halperson E., Matalon V., Goldstein G., Spilberg S.S., Herzog K., Fux-Noy A., et al. The prevalence of dental developmental anomalies among childhood cancer survivors according to types of anticancer treatment. Sci Rep 2022; 12 (1): 4485. DOI:10.1038/s41598-022-08266-148. Kaste S.C., Goodman P., Leisenring W., Stovall M., Hayashi R.J., Yeazel M., et al. Impact of radiation and chemotherapy on risk of dental abnormalities: a report from the Childhood Cancer Survivor Study. Cancer 2009; 115 (24): 5817–27. DOI:10.1002/cncr.24670Kaste S.C., Goodman P., Leisenring W., Stovall M., Hayashi R.J., Yeazel M., et al. Impact of radiation and chemotherapy on risk of dental abnormalities: a report from the Childhood Cancer Survivor Study. Cancer 2009; 115 (24): 5817–27. DOI:10.1002/cncr.2467049. Remmers D., Bökkerink J.P.M., Katsaros C. Microdontia after chemotherapy in a child treated for neuroblastoma. Orthod Craniofac Res 2006; 9 (4): 206–10. DOI:10.1111/j.1601-6343.2006.00374.xRemmers D., Bökkerink J.P.M., Katsaros C. Microdontia after chemotherapy in a child treated for neuroblastoma. Orthod Craniofac Res 2006; 9 (4): 206–10. DOI:10.1111/j.1601-6343.2006.00374.x50. Kushner B.H., Roberts S.S., Friedman D.N., Kuk D., Ostrovnaya I., Modak S., et al. Osteochondroma in long-term survivors of high-risk neuroblastoma. Cancer 2015; 121 (12): 2090–6. DOI:10.1002/cncr.29316Kushner B.H., Roberts S.S., Friedman D.N., Kuk D., Ostrovnaya I., Modak S., et al. Osteochondroma in long-term survivors of high-risk neuroblastoma. Cancer 2015; 121 (12): 2090–6. DOI:10.1002/cncr.2931651. Martin A., Schneiderman J., Helenowski I.B., Morgan E., Dilley K., Danner-Koptik K., et al. Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma. Pediatr Blood Cancer 2014; 61 (8): 1350–6. DOI:10.1002/pbc.25033Martin A., Schneiderman J., Helenowski I.B., Morgan E., Dilley K., Danner-Koptik K., et al. Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma. Pediatr Blood Cancer 2014; 61 (8): 1350–6. DOI:10.1002/pbc.2503352. Huibregtse K.E., DuBois S.G., Fetzko S., Fetzko S., Neuhaus J., Batra V., et al. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131) I-metaiodobenzylguanidine. Eur J Cancer 2016; 66: 144–52. DOI:10.1016/j.ejca.2016.07.017Huibregtse K.E., DuBois S.G., Fetzko S., Fetzko S., Neuhaus J., Batra V., et al. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131) I-metaiodobenzylguanidine. Eur J Cancer 2016; 66: 144–52. DOI:10.1016/j.ejca.2016.07.017